Following a successful presentation at the Cell Therapy Manufacturing and Gene Therapy Congress in Brussels, Onyx has again had a strong presence at the prestigious World Orphan Drugs Congress in Washington. This emphasises Onyx strong and continuing commitment to the areas of orphan drugs, rare and ultra-rare diseases and regenerative medicine including cell and gene therapies.
The WHO Global Patient Safety Action Plan 2021-2030 is a key document that outlines the changes and aspirations that the WHO has for the next decade around protection and wellbeing of patients. The plan, produced on 3 August 2021, aims to educate various stakeholders (NHS, HCPs, pharma and patient groups) about current issues surrounding patient safety and outline their proposed solutions1. The main goal over the next 10 years is a ‘zero harm philosophy’1. This means that although it’s impossible to totally wipe out errors in patient safety, the goal is to work towards being as close to zero harm as possible. But why are we telling you about it now? Because it’s World Patient Safety Day!read more >>
Once considered science fiction, a number of different gene therapy approaches are now being adopted in clinical practice to target a range of diseases. Our Prime Omics team discuss ‘overcoming the challenges of gene therapy’ in their whitepaper. Read the full piece below.
read more >>
We’re delighted with the success of our first annual Patient Engagement Day, held on 1 September 2021. The day was a real opportunity for partners in the patient engagement space to join conversations, support best practices and drive new ideas and innovation that help to bridge that gap between pharma and patients.
read more >>